Evidence map›Paper›PMID 24740298›Full record

ArticlePloS one2014

Human fibroblast reprogramming to pluripotent stem cells regulated by the miR19a/b-PTEN axis.

Xiaoping He, Yang Cao, Lihua Wang, Yingli Han, Xiuying Zhong, Guixiang Zhou, Yongping Cai, Huafeng Zhang, Ping Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. PTEN Inhibition in Human Disease Therapy.Molecules (Basel, Switzerland) · 2018
    Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoping HeInnovation Center for Cell Biology, School of Life Science, University of Science and Technology of China, Hefei, China.
Yang CaoInnovation Center for Cell Biology, School of Life Science, University of Science and Technology of China, Hefei, China.
Lihua WangInnovation Center for Cell Biology, School of Life Science, University of Science and Technology of China, Hefei, China.
Yingli HanInnovation Center for Cell Biology, School of Life Science, University of Science and Technology of China, Hefei, China.
Xiuying ZhongInnovation Center for Cell Biology, School of Life Science, University of Science and Technology of China, Hefei, China.
Guixiang ZhouCenter for Reproductive Medicine, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China.
Yongping CaiDepartment of Pathology, School of Medicine, Anhui University, Hefei, China.
Huafeng ZhangInnovation Center for Cell Biology, School of Life Science, University of Science and Technology of China, Hefei, China.
Ping GaoInnovation Center for Cell Biology, School of Life Science, University of Science and Technology of China, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induction of pluripotent stem cells (iPSC) by defined transcription factors is the recognized canonical means for somatic reprogramming, however, it remains incompletely understood how individual transcription factors affect cell fate decisions during the reprogramming process. Here, we report induction of fibroblast reprogramming by various transcriptional factors is mediated by a miR19a/b-PTEN axis. cMyc, one of the four Yamanaka factors known to stimulate both somatic cell reprogramming and tumorigenesis, induced the expression of multiple mircoRNAs, miR-17 ∼ 92 cluster in particular, in the early stage of reprogramming of human fibroblasts. Importantly, miR-17 ∼ 92 cluster could greatly enhance human fibroblast reprogramming induced by either the four Yamanaka factors (Oct4, Sox2, Klf4, and cMyc, or 4F) or the first three transcriptional factors (Oct4, Sox2, and Klf4, or 3F). Among members of this microRNA cluster, miR-19a/b exhibited the most potent effect on stimulating fibroblst reprogramming to iPSCs. Additional studies revealed that miR-19a/b enhanced iPSC induction efficiency by targeted inhibition of phosphatase and tensin homolog (PTEN), a renowned tumor suppressor whose loss-of-function mutations were found in multiple human malignancies. Our results thus demonstrate an important role of miR-19a/b-PTEN axis in the reprogramming of human fibroblasts, illustrating that the somatic reprogramming process and its underlying regulation pathways are intertwined with oncogenic signaling in human malignancies.

Indexed as

Cellular ReprogrammingCell DifferentiationCell LineFibroblastsGene Expression RegulationGenetic VectorsHumansInduced Pluripotent Stem CellsKruppel-Like Factor 4Kruppel-Like Transcription FactorsMicroRNAsOctamer Transcription Factor-3Proto-Oncogene Proteins c-mycPTEN PhosphohydrolaseRetroviridaeRNA, Long NoncodingKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsMicroRNAsMIR17HG, humanMIRN19A microRNA, humanOctamer Transcription Factor-3POU5F1 protein, humanProto-Oncogene Proteins c-mycPTEN PhosphohydrolasePTEN protein, humanRNA, Long NoncodingSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID24740298
PMCPMC3989277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.